GLP-1 Weight Loss Medications in 2026: Comparing Semaglutide, Tirzepatide, and the New Oral Option

A new generation of prescription weight loss medications has reshaped obesity treatment, moving far beyond the old calorie-counting framework. GLP-1 receptor agonists — drugs that mimic a naturally occurring hormone tied to appetite and blood sugar regulation — have become the dominant class, helping patients feel fuller faster, reduce cravings, and sustain weight loss over months or years. The key players are semaglutide (weekly injection), tirzepatide (weekly injection), liraglutide (daily injection), and a newly approved oral tablet called Foundayo.

Semaglutide, the active ingredient in well-known branded products, is backed by the STEP-1 trial, which showed participants losing an average of roughly 15% of body weight over 68 weeks when paired with lifestyle changes. Tirzepatide goes further by targeting both GLP-1 and GIP receptors simultaneously — a dual-hormone mechanism that produced average weight reductions approaching or exceeding 20% in the SURMOUNT-1 trial, depending on dosage, making it the most potent option currently studied. Liraglutide, the oldest of the group, requires daily dosing and produces more modest results, but remains clinically relevant for certain patients.

The newest entrant is Foundayo, which contains orforglipron — the first once-daily oral GLP-1 receptor agonist approved for weight management. Unlike injectable options, it can be taken at any time, with or without food, eliminating the fasting or water requirements associated with earlier oral semaglutide formulations. In 72-week clinical studies, Foundayo users lost between 7% and 11% of body weight on standard doses, with higher investigational doses pushing average reductions past 12%. For patients who have avoided GLP-1 therapy due to needle aversion, it represents a meaningful shift in accessibility.

Prescription eligibility generally requires a BMI of 30 or above, or 27-plus with at least one weight-related condition such as type 2 diabetes, high blood pressure, or sleep apnea. Common side effects — nausea, vomiting, diarrhea, constipation — tend to cluster during dose escalation and often ease over time. Clinicians and patients should also note that weight regain is a documented risk after discontinuing therapy, reinforcing that these drugs are long-term management tools, not short-course fixes.